medigraphic.com
ISSN 1561-3070 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cub Oftal 2014; 27 (2)

Permeabilizing probing for the treatment of obstructive meibonian gland dysfunction

Cárdenas DT, Cruz ID, Hernández LI, Guerra AM, Ruiz CR

Language: Spanish
References: 32
Page: 301-310
PDF size: 213.11 Kb.


ABSTRACT

Dry eye is one of the main eye surface diseases that make people go to the ophthalmological service. Seventy percent of patients with such diagnosis present with some type of symptoms related to the meibonian gland disease and its control with the regular treatments remains a problem. Hot pads and washing using shampoo for children give temporary relief, but are generally the patients do not comply with them for a long period of time. Another approach is the meibonian gland expression, which is uncomfortable and the treatment should be repeated more than once. Hence, the surgical probing seems to be a good alternative. Probing with Maskin probes introduced in 2009 is a new therapeutic variant which, according to the authors, had not been practiced in Cuba before. The lack of this type of probes in Cuba was the main incentive for their design in order to create permeabilization of the excretory ducts in the obstructive meibonian gland dysfunction, and to implement this technique. The devise was built with the resources of the lab prototype shop, taking the anatomical characteristics of the glandular system into consideration. The probes are presently used on a regular basis by ophthalmologists with encouraging results as in the reported cases.


REFERENCES

  1. Stern M. Ojo seco: ¿enfermedad o consecuencia natural de la edad? Arch. Soc. Esp. Oftalmol. 2005;80(3):129-31.

  2. Internacional Dry Eye workshop (DEWS). The Ocular Surface. 2007;5(2):65-204.

  3. Lemp M. Advances in understanding and managing dry eyes disease. Am J Ophthalmol. 2008;146(3):350- 6.

  4. Mathers WD. Why the eye becomes dry. A cornea and lacrimal gland feedback model. CLAO J. 2000;26(3):159-65.

  5. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on Meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci. 2011;52(4):1922-9.

  6. Maher I. Procedure helping clear up chronic dry eye. St. Petersburg: Times, Fla. August 11, 2010 [citado 5 de diciembre de 2013]. Disponible en: http://www.tampabay.com/news/health/procedure-helping-clear-up-chronic-dryeye/ 1114653

  7. Korb DR, Blackie CA. Meibomian gland diagnostic expressibility: correlation with dry eye symptoms and gland location. Cornea. 2008;27(10):1142-47.

  8. Obata H. Anatomy and histopathology of human meibomian gland. Cornea. 2002;21(7 Suppl):S70-4.

  9. Blackie CA, Korb DR, Knop E, Bedi R, Knop N, Holland EJ. Nonobvious obstructive meibomian gland dysfunction. Cornea. 2010;29(12):1333-45.

  10. Pult H, Riede-Pult BH. Non-contact meibography in diagnosis and treatment of non-obvious meibomian gland dysfunction. J Optom. 2012;5(1):2-5

  11. Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011;52(4):1994-2005.

  12. Murube J, Benítez del Castillo JM, Chen Zhuo L, Berta A, Rolando M. Triple clasificación de Madrid para el Ojo seco. Arch Soc Esp Oftalmol. 2003;78(11):587-93.

  13. Murube J, Németh J, Kaynak-Hekimhan P. The triple classification of dry eye for practical clinical use. Eur J Ophthalmol. 2005;15(6):660-7.

  14. Lemp M. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007;5(2):75-92.

  15. Nelson JD, Shimazaki J, Benítez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2011;52(4):1930-7.

  16. Knop E, Knop N, Millar T. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011;52(4):1938-78.

  17. Jester JV, Nicolaides N, Smith RE. Meibomian gland dysfunction. Keratin protein expression in normal human and rabbit meibomian glands. Invest Ophthalmol Vis Sci. 1989;30(5):927-35.

  18. Matsumoto Y, Shigeno Y, Sato EA, et al. The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy. Graefes Arch Clin Exp Ophthalmol. 2009;247(6):821-9.

  19. Qazi Y, Cavalcanti B, Cruzat A, et al. Immune response in meibomian gland dysfunction (MGD) and the effect of anti-inflammatory therapy: an in vivo confocal microscopy (IVCM) study. ARVO Meeting Abstracts. March 26, 2012;53(6):593.

  20. Hamrah P, Qazi Y, Blackie CA, Korb DR. Subclinical inflammation may explain the persistence of refractory dry eye symptoms after apparently successful treatment for meibomian gland dysfunction. ARVO Meeting Abstracts. March 26, 2012;53(6):594.

  21. Obata H, Yamamoto S, Horiuchi H, Machinami R. Histopathologic study of human lacrimal gland. Statistical analysis with special reference to aging. Ophthalmology. 1995;102(4):678-86.

  22. Cher I. The simple meibomian dimple. In: Lass J (ed). Advances in corneal research. Selected Transactions of the World Congress on the Cornea IV. London: Plenum Press; 1996. p. 27-35.

  23. Geerling G, Tauber J, Baudouin C. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;52(4): 2050-64.

  24. Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive MGD. Invest Ophthalmol Vis Sci. 2009;50(5):4636.

  25. Maskin SL. Meibomian gland probing findings suggest fibrotic obstruction is a major cause of obstructive meibomian gland dysfunction (O-MGD). Invest Ophthalmol Vis Sci. 2012;53(6):605.

  26. Maskin SL. Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction. Cornea. 2010;29 (10):1145-52.

  27. Maskin SL, Kantor K. Intraductal meibomian gland probing with adjunctive intraductal microtube steroid injection (MGPs) for meibomian gland dysfunction (MGD). Invest Ophthalmol Vis Sci. 2011;52(6):3817.

  28. Maskin SL, Warsinski C. Long term safety and retreatment data after intraductal meibomian gland probing for obstructive meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2010;51(5):6283.

  29. Caceres V. Probe aims to relieve symptoms of MGD. ASCRS Eye World Contributing Editor. Ophthalmology News. April 2010 [citado 5 diciembre 2013]. Disponible en: http://www.eyeworld.org/article-probe-aims-to-relieve-symptomsof- mgd

  30. Charters L. Probing benefits meibomian gland dysfunction Use with intraductal steroid tolerated; no adverse sequelae. Ophthalmology times. 2011 [citado 5 diciembre 2013];15. Disponible en: http://ophthalmologytimes.modernmedicine.com/ ophthalmologytimes/news/modernmedicine/modern-medicine-featurearticles/ probing-benefits-meibomian-g

  31. Maskin L. Dry Eye Relief. Peeling back layers to reveal root causes, select the right tools and improve tear quality. Ophthalmology Manegement. 2011; [citado 5 diciembre 2013]. Disponible en: http://www.ophthalmologymanagement.com/articleviewer.aspx?articleId=105865

  32. Maskin L. Intraductal Meibomian Gland Probes. Refractive Eyecare. 2012; [citado 5 diciembre 2011]. Disponible en: http://www.refractiveeyecare.com/2012/07/intraductal-meibomian-gland-probes/




2020     |     www.medigraphic.com